We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) closed at $855.35 in the latest trading session, marking a +1.14% move from the prior day. This change outpaced the S&P 500's 0.28% loss on the day. At the same time, the Dow lost 0.52%, and the tech-heavy Nasdaq lost 0.08%.
Shares of the drugmaker have appreciated by 12.07% over the course of the past month, outperforming the Medical sector's gain of 3.31%, and the S&P 500's gain of 4.03%.
The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company is scheduled to release its earnings on October 30, 2025. The company's upcoming EPS is projected at $6.38, signifying a 440.68% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $16.06 billion, indicating a 40.38% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $22.95 per share and revenue of $61.72 billion, indicating changes of +76.67% and +37.03%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.26% lower. Currently, Eli Lilly is carrying a Zacks Rank of #3 (Hold).
From a valuation perspective, Eli Lilly is currently exchanging hands at a Forward P/E ratio of 36.85. This indicates a premium in contrast to its industry's Forward P/E of 14.65.
One should further note that LLY currently holds a PEG ratio of 1.19. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry had an average PEG ratio of 1.59 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 59, this industry ranks in the top 24% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
Eli Lilly (LLY - Free Report) closed at $855.35 in the latest trading session, marking a +1.14% move from the prior day. This change outpaced the S&P 500's 0.28% loss on the day. At the same time, the Dow lost 0.52%, and the tech-heavy Nasdaq lost 0.08%.
Shares of the drugmaker have appreciated by 12.07% over the course of the past month, outperforming the Medical sector's gain of 3.31%, and the S&P 500's gain of 4.03%.
The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company is scheduled to release its earnings on October 30, 2025. The company's upcoming EPS is projected at $6.38, signifying a 440.68% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $16.06 billion, indicating a 40.38% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $22.95 per share and revenue of $61.72 billion, indicating changes of +76.67% and +37.03%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.26% lower. Currently, Eli Lilly is carrying a Zacks Rank of #3 (Hold).
From a valuation perspective, Eli Lilly is currently exchanging hands at a Forward P/E ratio of 36.85. This indicates a premium in contrast to its industry's Forward P/E of 14.65.
One should further note that LLY currently holds a PEG ratio of 1.19. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry had an average PEG ratio of 1.59 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 59, this industry ranks in the top 24% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.